Carfilzomib vs TQB3602
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: Proteasome · full Multiple Myeloma pipeline
Carfilzomib
Marketed by Amgen and partners
NCT01080391 · Phase 3 · completed
The 792 participants were randomly assigned to carfilzomib plus lenalidomide and dexamethasone or to lenalidomide and dexamethasone, but treatment was open-label rather than blinded. The primary clinical endpoint, progression-free survival, was met, with a median of 26.3 versus 17.6 months and a statistically significant difference (p<0.0001).
Next expected readout: November 2026 · NCT04973605 (registry estimate)
Reported efficacy
Progression-free Survival (PFS) as Assessed by the Independent Review Committee (PA DCO Only) (From randomization until the PA DCO date of 14 July 2019; the longest treatment duration as of the DCO was 102.3 weeks): Progression-free Survival (PFS) as Assessed by the Independent Review Committee (PA DCO Only) (From randomization until the PA DCO date of 14 July 2019; the longest treatment duration as of the DCO was 102.3 weeks): Kd - Carfilzomib and Dexamethasone — Participants with PFS events: 68 Participants; Participants who were censored: 86 Participants | KdD - Carfilzomib, Dexamethasone and Daratumumab — Participants with PFS events: 110 Participants; Participants who were censored: 202 Participants (met)
Result source: NCT03158688
TQB3602
Developed by Sino Biopharmaceutical
NCT04275583 · Phase 1 · status unknown
This is a small, open-label, single-arm, non-randomized dose-finding study designed to establish tolerability rather than to test clinical benefit, with no comparator arm and no blinding. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
These results cover the 25-patient dose-escalation phase; the study's dose-expansion phase is not included.
Reported efficacy
Dose-limiting toxicity (DLT) (Baseline up to 28 days): Twenty-five patients with relapsed/refractory multiple myeloma who had relapsed or failed at least 2 lines of therapy were enrolled in the dose-escalation phase. Two patients in the 7.0 mg dose group developed dose-limiting toxicities, giving a maximum tolerated dose of 6.0 mg. Any-grade adverse events occurred in 24 (96.0%) patients and grade >=3 adverse events in 13 (52.0%). Among 22 response-evaluable patients, 63.7% achieved stable disease or better.
Result source: NCT04275583
Results for Multiple Myeloma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
PFS, median
- Carfilzomib
- 26.3 vs 17.6vs Lenalidomide and Dexamethasone (Rd)NCT01080391
35 other results
- 35.6 vs 19.1 NCT03275285
- 41.7 vs 20.8 NCT03275285
- 18.7 vs 9.4 NCT01568866
- 22.3 vs 22.1 NCT01818752
- 11.2 NCT02412878
- 7.6 NCT02412878
- 3.7 vs 3.3 NCT01302392
- 5 NCT01903811
- 8 NCT01903811
- 15.3 NCT01677858
- 16.2 NCT01677858
- 3.7 NCT00511238
- 6.9 NCT00531284
- 1.8 NCT00531284
- 4.6 NCT00530816
- 8.2 NCT00530816
- 3.5 NCT00511238
- 12.9 NCT01677858
- 1.6 NCT00531284
- 21 NCT01677858
- 1.5 NCT00531284
- 1 NCT00531284
- 11.5 NCT00531284
- 2.9 NCT00531284
- 1.4 NCT00531284
- 4.6 NCT00531284
- 4.6 NCT00531284
- 1.8 NCT00531284
- 1.7 NCT00531284
- 3.8 NCT01775553
- 9.4 NCT00531284
- 13.6 NCT01677858
- 5.2 NCT00531284
- 1.8 NCT00531284
- 5.1 NCT00531284
- TQB3602
- —Not reported
OS, median
- Carfilzomib
- 10.2 vs 10+0.2 vs placeboNCT01302392
10 other results
- 48.3 vs 40.4 NCT01080391
- 47.6 vs 40 NCT01568866
- 50.8 vs 43.6 NCT03158688
- 15.2 NCT03029234
- 15.4 NCT00511238
- 15.6 NCT00511238
- 37.3 NCT00530816
- 45.6 NCT00530816
- 26 NCT01903811
- 22 NCT01903811
- TQB3602
- —Not reported
ORR
- Carfilzomib
- 82.5%bNCT03859427
56 other results
- 86.3% NCT03859427
- 35.8% NCT03029234
- 87.1% vs 66.7% NCT01080391
- 86.6% vs 82.9% NCT03275285
- 76.9% vs 62.6% NCT01568866
- 84.3% vs 74.7% NCT03158688
- 84.3% vs 78.8% NCT01818752
- 62.9% NCT02412878
- 40.8% NCT02412878
- 35.8% NCT03029234
- 35% NCT03029234
- 35% NCT03029234
- 74.2% NCT01677858
- 76.9% NCT01677858
- 15.4% NCT00531284
- 53% NCT00530816
- 16.1% NCT00530816
- 39.6% NCT00530816
- 88.1% NCT03412565
- 90.8% NCT03412565
- 84.8% NCT03412565
- 66.7% NCT01677858
- 93.3% NCT01677858
- 100% NCT01677858
- 33.3% NCT01677858
- 50% NCT00531284
- 38.5% NCT00531284
- 52.2% NCT00530816
- 17.1% NCT00530816
- 42.4% NCT00530816
- 97% NCT03412565
- 59.2% NCT03934684
- 53.8% NCT03934684
- 97.8% NCT01402284
- 36.4% NCT00531284
- 10% NCT00531284
- 0% NCT00531284
- 100% NCT00531284
- 37.5% NCT00531284
- 28.6% NCT00531284
- 50% NCT00531284
- 64.3% NCT00531284
- 25% NCT00721734
- 37.5% NCT00721734
- 50% NCT00531284
- 0% NCT00531284
- 33.3% NCT00531284
- 42.9% NCT00531284
- 33.3% NCT00531284
- 50% NCT00531284
- 0% NCT00531284
- 18.2% NCT00721734
- 27.3% NCT00721734
- 22.2% NCT00721734
- 100% NCT00531284
- 100% NCT00531284
- TQB3602
- —Not reported
VGPR or better
- Carfilzomib
- 72.6% vs 56.1%vs Carfilzomib + DexamethasoneNCT03275285
4 other results
- 71.6% NCT03412565
- 77.6% NCT03412565
- 80% NCT03412565
- 77.3% NCT03412565
- TQB3602
- —Not reported
MRD negativity
- Carfilzomib
- 18.3% vs 5.2%vs Carfilzomib and DexamethasoneNCT03158688
6 other results
- 18.9% NCT03859427
- 18.1% NCT03859427
- 44.4% NCT01402284
- 25.4% NCT03412565
- 21.5% NCT03412565
- 27.3% NCT03412565
- TQB3602
- —Not reported
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Carfilzomib: 4 of 4 rows · TQB3602: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Carfilzomib |
|---|---|
| Dropout rate | 1%a NCT01080391 · Phase 3 · combination · Multiple Myeloma · phase 3 show 68 more results0.6% NCT01302392 · Phase 3 · monotherapy · Multiple Myeloma · phase 3 n/a: no completion milestone NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3 —Carfilzomib NCT01568866 · Phase 3 89.7%Carfilzomib + DEX NCT01568866 · Phase 3 · combination 5.4%20/70 mg/m² once weekly NCT02412878 · Phase 3 · combination 8.8%20/27 mg/m² twice weekly NCT02412878 · Phase 3 · combination 67.3% NCT03158688 · Phase 3 · combination 71.6%D + Bortezomib + Melphalan + Predn NCT03412565 · Phase 2 · combination 1.5%Daratumumab (D)+Bortezomib+Lenalid NCT03412565 · Phase 2 · combination 77.3%Daratumumab + Carfilzomib + Dexame NCT03412565 · Phase 2 · combination 78.5%Daratumumab + Lenalidomide + Dexam NCT03412565 · Phase 2 · combination 57.1%20/70 mg/m² NCT00531284 · Phase 1/2 100%20/70 mg/m² NCT00531284 · Phase 1/2 100%20/70 mg/m² NCT00531284 · Phase 1/2 100%20/56 mg/m² NCT00531284 · Phase 1/2 100%20/56 mg/m² + Dex NCT00531284 · Phase 1/2 · combination 100%20/56 mg/m² NCT00531284 · Phase 1/2 100%20/56 mg/m² NCT00531284 · Phase 1/2 100%20/45 mg/m² NCT00531284 · Phase 1/2 85.7%20/45 mg/m² + Dex NCT00531284 · Phase 1/2 · combination 100%20/45 mg/m² NCT00531284 · Phase 1/2 100%45 mg/m² NCT00531284 · Phase 1/2 100%20/36 mg/m² NCT00531284 · Phase 1/2 85.7%20/36 mg/m² Bolus NCT00531284 · Phase 1/2 100%36 mg/m² NCT00531284 · Phase 1/2 96.9%20/36 mg/m² Bolus NCT00531284 · Phase 1/2 100%20/27 mg/m² Bolus NCT00531284 · Phase 1/2 100%20 mg/m² Bolus NCT00531284 · Phase 1/2 91.3%Carfilzomib (A0) NCT00511238 · Phase 2 85%Carfilzomib (A1) NCT00511238 · Phase 2 · pooled 58.6%20/27 mg/m² NCT00530816 · Phase 2 · pooled 74.3%20 mg/m² NCT00530816 · Phase 2 71.2%20 mg/m² NCT00530816 · Phase 2 92.3%Carfilzomib and Dexamethasone (Kd) NCT03934684 · Phase 4 · registry result, not featured evidence · combination 65.3%Carfilzomib, Lenalidomide and Dexa NCT03934684 · Phase 4 · registry result, not featured evidence · combination 16.2%20/56 mg/m^2 once weekly NCT03859427 · Phase 3 · registry result, not featured evidence · combination —20/27 mg/m^2 twice weekly NCT03859427 · Phase 3 · registry result, not featured evidence · combination 78.6% NCT03029234 · Phase 3 · registry result, not featured evidence · combination 41.4% NCT01818752 · Phase 3 · registry result, not featured evidence · combination 0% NCT02969837 · Phase 2 · registry result, not featured evidence — NCT01402284 · Phase 2 · registry result, not featured evidence · combination 11.1%low-dose NCT01903811 · Phase 2 · registry result, not featured evidence · combination 19.7%high-dose NCT01903811 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone NCT01775553 · Phase 2 · registry result, not featured evidence 20.5% NCT01351623 · Phase 2 · registry result, not featured evidence 75%Carfilzomib - Dialysis NCT00721734 · Phase 2 · registry result, not featured evidence 100%Carfilzomib - Mild RI NCT00721734 · Phase 2 · registry result, not featured evidence 80%Carfilzomib - Moderate RI NCT00721734 · Phase 2 · registry result, not featured evidence 66.7%Carfilzomib - Normal RF NCT00721734 · Phase 2 · registry result, not featured evidence 75%Carfilzomib - Severe RI NCT00721734 · Phase 2 · registry result, not featured evidence 0%56mg/m2/Dose NCT02937571 · Phase 1/2 · registry result, not featured evidence 0%45mg/m2/Dose NCT02937571 · Phase 1/2 · registry result, not featured evidence —MTD: Carfilzomib NCT02937571 · Phase 1/2 · registry result, not featured evidence 0%Dose Level 0 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination 0%Dose Level 1 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination 0%Dose Level 2 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination 0%Dose Level 3 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination —Dose Level 0 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination —Dose Level 1 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination —Dose Level 2 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination —Dose Level 3 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination 2.8%Dose Level 3 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination 100%88 mg/m² NCT01677858 · Phase 1/2 · registry result, not featured evidence 93.3%70 mg/m² NCT01677858 · Phase 1/2 · registry result, not featured evidence 95.5%70 mg/m² NCT01677858 · Phase 1/2 · registry result, not featured evidence 66.7%56 mg/m² NCT01677858 · Phase 1/2 · registry result, not featured evidence 100%45 mg/m² NCT01677858 · Phase 1/2 · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT01080391 · Phase 3 · combination · Multiple Myeloma · phase 3 show 68 more results— NCT01302392 · Phase 3 · monotherapy · Multiple Myeloma · phase 3 16.2% NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3 —Carfilzomib NCT01568866 · Phase 3 20.7%Carfilzomib + DEX NCT01568866 · Phase 3 · combination —20/70 mg/m² once weekly NCT02412878 · Phase 3 · combination —20/27 mg/m² twice weekly NCT02412878 · Phase 3 · combination — NCT03158688 · Phase 3 · combination —D + Bortezomib + Melphalan + Predn NCT03412565 · Phase 2 · combination —Daratumumab (D)+Bortezomib+Lenalid NCT03412565 · Phase 2 · combination —Daratumumab + Carfilzomib + Dexame NCT03412565 · Phase 2 · combination —Daratumumab + Lenalidomide + Dexam NCT03412565 · Phase 2 · combination 14.3%20/70 mg/m² NCT00531284 · Phase 1/2 0%20/70 mg/m² NCT00531284 · Phase 1/2 27.3%20/70 mg/m² NCT00531284 · Phase 1/2 33.3%20/56 mg/m² NCT00531284 · Phase 1/2 25%20/56 mg/m² + Dex NCT00531284 · Phase 1/2 · combination 20%20/56 mg/m² NCT00531284 · Phase 1/2 20.8%20/56 mg/m² NCT00531284 · Phase 1/2 0%20/45 mg/m² NCT00531284 · Phase 1/2 0%20/45 mg/m² + Dex NCT00531284 · Phase 1/2 · combination 50%20/45 mg/m² NCT00531284 · Phase 1/2 28.6%45 mg/m² NCT00531284 · Phase 1/2 0%20/36 mg/m² NCT00531284 · Phase 1/2 14.3%20/36 mg/m² Bolus NCT00531284 · Phase 1/2 0%36 mg/m² NCT00531284 · Phase 1/2 10.8%20/36 mg/m² Bolus NCT00531284 · Phase 1/2 25%20/27 mg/m² Bolus NCT00531284 · Phase 1/2 0%20 mg/m² Bolus NCT00531284 · Phase 1/2 28.3%Carfilzomib (A0) NCT00511238 · Phase 2 12.4%Carfilzomib (A1) NCT00511238 · Phase 2 · pooled 10%20/27 mg/m² NCT00530816 · Phase 2 · pooled 17.1%20 mg/m² NCT00530816 · Phase 2 22%20 mg/m² NCT00530816 · Phase 2 —Carfilzomib and Dexamethasone (Kd) NCT03934684 · Phase 4 · registry result, not featured evidence · combination —Carfilzomib, Lenalidomide and Dexa NCT03934684 · Phase 4 · registry result, not featured evidence · combination —20/56 mg/m^2 once weekly NCT03859427 · Phase 3 · registry result, not featured evidence · combination —20/27 mg/m^2 twice weekly NCT03859427 · Phase 3 · registry result, not featured evidence · combination — NCT03029234 · Phase 3 · registry result, not featured evidence · combination 15.5% NCT01818752 · Phase 3 · registry result, not featured evidence · combination — NCT02969837 · Phase 2 · registry result, not featured evidence — NCT01402284 · Phase 2 · registry result, not featured evidence · combination —low-dose NCT01903811 · Phase 2 · registry result, not featured evidence · combination —high-dose NCT01903811 · Phase 2 · registry result, not featured evidence · combination 7.7% NCT01775553 · Phase 2 · registry result, not featured evidence 9.1% NCT01351623 · Phase 2 · registry result, not featured evidence 37.5%Carfilzomib - Dialysis NCT00721734 · Phase 2 · registry result, not featured evidence 8.3%Carfilzomib - Mild RI NCT00721734 · Phase 2 · registry result, not featured evidence 40%Carfilzomib - Moderate RI NCT00721734 · Phase 2 · registry result, not featured evidence 25%Carfilzomib - Normal RF NCT00721734 · Phase 2 · registry result, not featured evidence 0%Carfilzomib - Severe RI NCT00721734 · Phase 2 · registry result, not featured evidence 0%56mg/m2/Dose NCT02937571 · Phase 1/2 · registry result, not featured evidence 0%45mg/m2/Dose NCT02937571 · Phase 1/2 · registry result, not featured evidence —MTD: Carfilzomib NCT02937571 · Phase 1/2 · registry result, not featured evidence —Dose Level 0 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination —Dose Level 1 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination —Dose Level 2 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination —Dose Level 3 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination —Dose Level 0 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination —Dose Level 1 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination —Dose Level 2 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination —Dose Level 3 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination —Dose Level 3 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination 50%88 mg/m² NCT01677858 · Phase 1/2 · registry result, not featured evidence 13.3%70 mg/m² NCT01677858 · Phase 1/2 · registry result, not featured evidence 14.6%70 mg/m² NCT01677858 · Phase 1/2 · registry result, not featured evidence 0%56 mg/m² NCT01677858 · Phase 1/2 · registry result, not featured evidence 0%45 mg/m² NCT01677858 · Phase 1/2 · registry result, not featured evidence |
| Serious AEs | 65.3%a NCT01080391 · Phase 3 · combination · Multiple Myeloma · phase 3 show 68 more results58.6% NCT01302392 · Phase 3 · monotherapy · Multiple Myeloma · phase 3 72.9% NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3 58.7%Carfilzomib NCT01568866 · Phase 3 —Carfilzomib + DEX NCT01568866 · Phase 3 · combination 49.6%20/70 mg/m² once weekly NCT02412878 · Phase 3 · combination 43.4%20/27 mg/m² twice weekly NCT02412878 · Phase 3 · combination 68.5% NCT03158688 · Phase 3 · combination 44.8%D + Bortezomib + Melphalan + Predn NCT03412565 · Phase 2 · combination 28.4%Daratumumab (D)+Bortezomib+Lenalid NCT03412565 · Phase 2 · combination 33.3%Daratumumab + Carfilzomib + Dexame NCT03412565 · Phase 2 · combination 56.9%Daratumumab + Lenalidomide + Dexam NCT03412565 · Phase 2 · combination 71.4%20/70 mg/m² NCT00531284 · Phase 1/2 100%20/70 mg/m² NCT00531284 · Phase 1/2 54.5%20/70 mg/m² NCT00531284 · Phase 1/2 33.3%20/56 mg/m² NCT00531284 · Phase 1/2 37.5%20/56 mg/m² + Dex NCT00531284 · Phase 1/2 · combination 50%20/56 mg/m² NCT00531284 · Phase 1/2 45.8%20/56 mg/m² NCT00531284 · Phase 1/2 0%20/45 mg/m² NCT00531284 · Phase 1/2 35.7%20/45 mg/m² + Dex NCT00531284 · Phase 1/2 · combination 83.3%20/45 mg/m² NCT00531284 · Phase 1/2 57.1%45 mg/m² NCT00531284 · Phase 1/2 50%20/36 mg/m² NCT00531284 · Phase 1/2 57.1%20/36 mg/m² Bolus NCT00531284 · Phase 1/2 33.3%36 mg/m² NCT00531284 · Phase 1/2 41.5%20/36 mg/m² Bolus NCT00531284 · Phase 1/2 25%20/27 mg/m² Bolus NCT00531284 · Phase 1/2 33.3%20 mg/m² Bolus NCT00531284 · Phase 1/2 43.5%Carfilzomib (A0) NCT00511238 · Phase 2 47.4%Carfilzomib (A1) NCT00511238 · Phase 2 · pooled 38.6%20/27 mg/m² NCT00530816 · Phase 2 · pooled 34.3%20 mg/m² NCT00530816 · Phase 2 30.5%20 mg/m² NCT00530816 · Phase 2 38.5%Carfilzomib and Dexamethasone (Kd) NCT03934684 · Phase 4 · registry result, not featured evidence · combination 22.4%Carfilzomib, Lenalidomide and Dexa NCT03934684 · Phase 4 · registry result, not featured evidence · combination 37.7%20/56 mg/m^2 once weekly NCT03859427 · Phase 3 · registry result, not featured evidence · combination 32.5%20/27 mg/m^2 twice weekly NCT03859427 · Phase 3 · registry result, not featured evidence · combination 55.3% NCT03029234 · Phase 3 · registry result, not featured evidence · combination 49.6% NCT01818752 · Phase 3 · registry result, not featured evidence · combination 39.1% NCT02969837 · Phase 2 · registry result, not featured evidence 42.2% NCT01402284 · Phase 2 · registry result, not featured evidence · combination 39.4%low-dose NCT01903811 · Phase 2 · registry result, not featured evidence · combination 47.4%high-dose NCT01903811 · Phase 2 · registry result, not featured evidence · combination 23.1% NCT01775553 · Phase 2 · registry result, not featured evidence 63.6% NCT01351623 · Phase 2 · registry result, not featured evidence 100%Carfilzomib - Dialysis NCT00721734 · Phase 2 · registry result, not featured evidence 66.7%Carfilzomib - Mild RI NCT00721734 · Phase 2 · registry result, not featured evidence 100%Carfilzomib - Moderate RI NCT00721734 · Phase 2 · registry result, not featured evidence 41.7%Carfilzomib - Normal RF NCT00721734 · Phase 2 · registry result, not featured evidence 75%Carfilzomib - Severe RI NCT00721734 · Phase 2 · registry result, not featured evidence 33.3%56mg/m2/Dose NCT02937571 · Phase 1/2 · registry result, not featured evidence 0%45mg/m2/Dose NCT02937571 · Phase 1/2 · registry result, not featured evidence 65.2%MTD: Carfilzomib NCT02937571 · Phase 1/2 · registry result, not featured evidence —Dose Level 0 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination —Dose Level 1 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination —Dose Level 2 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination —Dose Level 3 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination 100%Dose Level 0 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination 33.3%Dose Level 1 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination 66.7%Dose Level 2 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination 50%Dose Level 3 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination 45.7%Phase 2 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination —Dose Level 3 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination 16.7%88 mg/m² NCT01677858 · Phase 1/2 · registry result, not featured evidence 26.7%70 mg/m² NCT01677858 · Phase 1/2 · registry result, not featured evidence 39.3%70 mg/m² NCT01677858 · Phase 1/2 · registry result, not featured evidence 0%56 mg/m² NCT01677858 · Phase 1/2 · registry result, not featured evidence 33.3%45 mg/m² NCT01677858 · Phase 1/2 · registry result, not featured evidence |
| Most frequent reported AEs | a diarrhoea 43.4% anaemia 42.3% neutropenia 40.1% NCT01080391 · Phase 3 · combination · Multiple Myeloma · phase 3 show 62 more resultsanaemia 56.1% (placebo 47.1%) thrombocytopenia 36.9% (placebo 28.1%) pyrexia 26.1% (placebo 18.3%) NCT01302392 · Phase 3 · monotherapy · Multiple Myeloma · phase 3 infusion related reaction 45.2% upper respiratory tract infection 41.2% diarrhoea 40.7% NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3 20/70 mg/m² once weekly anaemia 29% hypertension 24.4% pyrexia 23.1% NCT02412878 · Phase 3 · combination 20/27 mg/m² twice weekly anaemia 31.1% diarrhoea 21.7% hypertension 20.9% NCT02412878 · Phase 3 · combination peripheral sensory neuropathy 41.8% constipation 38.8% neutropenia 37.3% NCT03412565 · Phase 2 · combination 20/56 mg/m² + Dex fatigue 62.5% pyrexia 50% upper respiratory tract infection 50% NCT00531284 · Phase 1/2 · combination 20/45 mg/m² + Dex fatigue 64.3% cough 57.1% upper respiratory tract infection 50% NCT00531284 · Phase 1/2 · combination cough 42.3% anaemia 36.5% pyrexia 26.9% NCT03934684 · Phase 4 · registry result, not featured evidence · combination cough 26.5% diarrhoea 18.4% hypertension 18.4% NCT03934684 · Phase 4 · registry result, not featured evidence · combination 20/56 mg/m^2 once weekly neutropenia 29.1% anaemia 25.1% hypertension 21.5% NCT03859427 · Phase 3 · registry result, not featured evidence · combination 20/27 mg/m^2 twice weekly neutropenia 31.6% hypertension 24.2% anaemia 23.8% NCT03859427 · Phase 3 · registry result, not featured evidence · combination anaemia 61.8% platelet count decreased 48.8% upper respiratory tract infection 48.8% NCT03029234 · Phase 3 · registry result, not featured evidence · combination anaemia 35.4% pyrexia 35.4% nausea 35.2% NCT01818752 · Phase 3 · registry result, not featured evidence · combination fatigue 63% diarrhea 45.7% edema limbs 37% NCT02969837 · Phase 2 · registry result, not featured evidence lymphocyte count decreased 100% hypoalbuminemia 93.3% platelet count decreased 93.3% NCT01402284 · Phase 2 · registry result, not featured evidence · combination low-dose anemia 59.1% fatigue 59.1% platelet count decreased 42.4% NCT01903811 · Phase 2 · registry result, not featured evidence · combination high-dose anemia 66.7% fatigue 57.9% platelet count decreased 50.9% NCT01903811 · Phase 2 · registry result, not featured evidence · combination anemia 61.5% hypertension 53.8% platelet count decreased 53.8% NCT01775553 · Phase 2 · registry result, not featured evidence diarrhea 65.9% nausea 59.1% fatigue 54.5% NCT01351623 · Phase 2 · registry result, not featured evidence anaemia 62.5% thrombocytopenia 62.5% abdominal pain 50% NCT00721734 · Phase 2 · registry result, not featured evidence fatigue 75% anaemia 58.3% constipation 50% NCT00721734 · Phase 2 · registry result, not featured evidence anaemia 62.5% fatigue 50% dyspnoea 37.5% NCT00721734 · Phase 2 · registry result, not featured evidence 56mg/m2/Dose anxiety 33.3% hyperkalemia 33.3% hypertension 33.3% NCT02937571 · Phase 1/2 · registry result, not featured evidence 45mg/m2/Dose lymphocyte count decreased 66.7% skin infection 66.7% alanine aminotransferase increased 33.3% NCT02937571 · Phase 1/2 · registry result, not featured evidence lymphocyte count decreased 73.9% neutrophil count decreased 65.2% white blood cell decreased 60.9% NCT02937571 · Phase 1/2 · registry result, not featured evidence Dose Level 0 anemia 100% cd4 lymphocytes decreased 100% lymphocyte count decreased 100% NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination Dose Level 1 anemia 100% lymphocyte count decreased 100% neutrophil count decreased 100% NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination Dose Level 2 hypotension 100% lymphocyte count decreased 100% neutrophil count decreased 100% NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination Dose Level 3 anemia 100% platelet count decreased 100% white blood cell decreased 100% NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination platelet count decreased 100% lymphocyte count decreased 91.4% white blood cell decreased 91.4% NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination 88 mg/m² headache 66.7% fatigue 50% insomnia 50% NCT01677858 · Phase 1/2 · registry result, not featured evidence 70 mg/m² upper respiratory tract infection 80% diarrhoea 60% fatigue 60% NCT01677858 · Phase 1/2 · registry result, not featured evidence 70 mg/m² fatigue 52.8% nausea 40.4% insomnia 32.6% NCT01677858 · Phase 1/2 · registry result, not featured evidence 56 mg/m² anaemia 66.7% arthralgia 66.7% cardiac murmur 66.7% NCT01677858 · Phase 1/2 · registry result, not featured evidence 45 mg/m² fatigue 100% back pain 66.7% diarrhoea 66.7% NCT01677858 · Phase 1/2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 66 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Carfilzomib
show 7 more results
show 5 more results
show 4 more results
show 4 more results
show 1 more result
show 2 more results
show 1 more result
+ 118 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Carfilzomib's landscape · TQB3602's landscape